Resveratrol-Containing Compositions And Methods Of Use

• US 20120058088A1
• Filed: 06/27/2011
• Published: 03/08/2012
• Est. Priority Date: 06/28/2010
• Status: Abandoned Application

• Current Assignee: Resveratrol Partners, LLC
• Original Assignee: Resveratrol Partners, LLC
• Inventors: Sardi, William
• Application Number:
  US13/169,650
• Publication Number:
  US 20120058088A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, and one or more additional antioxidants such as phenolic antioxidants or vitamin D.

Claims

1. A method of modulating a biological activity in a human subject, comprising:

administering to a human subject in need thereof a composition comprising

trans-resveratrol in an amount of 0.25 to 5 mg per kilogram of the human subject,

a metal chelating agent, and

one or more additional antioxidants,

wherein said administration is effective to modulate a biological activity in the human subject as compared to administration of resveratrol alone.

2. The method of claim 1, wherein the metal chelating agent comprises phytic acid.

3. The method of claim 1, wherein the metal chelating agent is present in an amount of 0.25 to 5 mg per kilogram of the human subject.

4. The method of claim 1, wherein the one or more additional antioxidants are present in an amount of 0.05 to 2 mg per kilogram of the human subject.

5. The method of claim 1, wherein the one or more additional antioxidants comprises a phenolic antioxidant.

6. The method of claim 5, wherein the phenolic antioxidant is selected from the group consisting of apigenin, caffeic acid, epigallocatechin 3-gallate (EGCG), ferulic acid, and quercetin.

7. The method of claim 1, wherein the one or more additional antioxidants comprises Vitamin D.

8. The method of claim 1, wherein the composition further comprises one or more glycosaminoglycans selected from the group consisting of hyaluronic acid and chondroitin sulfate.

9. The method of claim 1, wherein the modulation of a biological activity comprises treating or preventing a disease or condition selected from the group consisting of cardiovascular disease, cancer, macular degeneration, a disease associated with aging, a neurodegenerative disease, and inflammation.

10. The method of claim 1, wherein the modulation of a biological activity comprises modulating the expression of a survival or longevity gene.

11. The method of claim 10, wherein the survival or longevity gene is selected from the group consisting of Sirtuin 1, Sirtuin 3, forkhead Foxo1 transcription factor, uncoupling protein 3, or pyruvate dehydrogenase kinase 4.

12. The method of claim 1, wherein the modulation of a biological activity comprises modulating a biological activity selected from the group consisting of oxidative phosphorylation, actin filament length or polymerization, intracellular transport, organelle biogenesis, insulin signaling, glycolysis, gluconeogenesis, and fatty acid metabolism.

13. A method of improving cell transplantation therapy in a human subject, comprising:

co-administering to a human subject transplanted cells and a composition comprising

trans-resveratrol in an amount of 0.25 to 5 mg per kilogram of the human subject,

a metal chelating agent, and

one or more additional antioxidants,

wherein said co-administration is effective to improve the effectiveness of the cell transplantation in the human subject as compared to administration of the transplanted cells alone.

14. The method of claim 13, wherein the co-administration is effective to improve survival of the transplanted cells.

15. The method of claim 13, wherein the co-administration is effective to improve proliferation of the transplanted cells.

16. The method of claim 13, wherein the transplanted cells are selected from the group consisting of cardiac stem cells, neural stem cells, and retinal pigment epithelial (RPE) cells.

17. The method of claim 13, wherein the transplanted cells are cardiac stem cells, and wherein the co-administration is effective to improve differentiation of the cardiac stem cells.

18. A method of improving treatment of macular degeneration in a human subject, comprising:

administering to a human subject suffering from macular degeneration or macular dystrophy a composition comprising

trans-resveratrol in an amount of 0.25 to 5 mg per kilogram of the human subject,

a metal chelating agent, and

one or more additional antioxidants,

wherein said administration is effective to improve the effectiveness of the macular degeneration treatment in the human subject as compared to administration of resveratrol alone.

19. The method of claim 18, wherein the administration is effective to provide one or more benefits selected from the group consisting of improved eyesight, shrinkage of visual defects, and decreased drusen in the eye.

20. The method of claim 18, further comprising co-administering to the human subject the composition and a macular degeneration treatment is selected from the group consisting of an anti-angiogenic medicament and an anti-drusen medicament.